New Research Reports

We maintain our BUY recommendation on the stock.

CA Grameen (Grameen) continued to improve on asset quality metrics in Q1FY26: monthly PAR 15+ accretion rate fell to 0.46% in Jun’25 vs. 0.84% in Mar’25 vs. 1.34% in Nov’24 and credit cost fell for the straight third quarter with total provisions at INR 5.7bn in Q1FY26 vs INR 5.8bn in Q4FY25 vs INR 7.5bn in Q3FY25.

CreditAccess Grameen’s (CREDAG) 1QFY26 PAT stood at INR602m (vs. est. INR842m). NII declined ~2% YoY to ~INR9b (in line). PPOP fell ~8% YoY to INR6.5b (in line).

We maintain our BUY recommendation on the stock.

AU SFB reported weak core performance, with margins declining sharply by 40bps QoQ to 5.4%, although higher treasury gains and surprisingly lower nonstaff opex, amid bidding for a Universal Banking license led to a ~6% PAT beat, at Rs5.8bn/1.5% RoA.

AU Small Finance Bank (AUBANK) reported a 1QFY26 PAT of INR5.81b (5% beat; up 15% QoQ) amid robust other income and controlled opex.

Diversifying to secured segments; rebalancing unsecured book to relatively high-yield IL from MGL

declined by 10 bps compared to FY24, settling at 12.9%. Operating expenses increased by 11.0% YoY to Rs.1,108 cr. in FY25, while a decline in fee and other income led to a marginal rise in the cost-to-income ratio to 30.7%, up from 30.5% in the previous year. Despite a sharp 327.1% YoY increase in provisions due to accelerated write-offs targeting delinquent accounts, the company reported an annual profit of Rs.531.4 cr. Gross NPA and Net NPA rose sharply to 4.8% and 1.7%, respectively, from 1.2% and 0.4% in FY24, reflecting a notable deterioration across all PAR buckets. While collection efficiency remained subdued for the first three quarters of the year, it showed signs of recovery towards the end of FY25, indicating early momentum in asset quality stabilization....

Overall, FY25 has been tough owing to higher interest rates, tight liquidity, and high stress in unsecured loans. Profitability is expected to rebound from H2FY26 as headwinds recede on the margin and asset quality fronts.

We recommend a BUY rating on the stock with a target price of Rs 74/share, implying an upside of 11% from the CMP.